Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Bausch Health Companies Inc. Common Stock (TSX: BHC )

9.960 +0.210 (+2.15%)
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 13, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 273,054
Open 9.740
Bid (Size) 9.600 (20)
Ask (Size) 9.980 (8)
Prev. Close 9.750
Today's Range 9.600 - 9.970
52wk Range 5.450 - 15.43
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Bausch Health Announces Fourth Quarter and Full-Year 2024 Results
Via ACCESS Newswire
Bausch Health to Participate in the J.P. Morgan Global Leveraged Finance Conference
Via ACCESS Newswire

Performance

YTD
-12.78%
-12.78%
1 Month
+10.06%
+10.06%
3 Month
-7.18%
-7.18%
6 Month
+14.88%
+14.88%
1 Year
-19.68%
-19.68%

More News

Read More
Bausch Health Announces 2025 Salix Gastrointestinal Health Scholars Program
Via ACCESS Newswire
Bausch Health Provides Update on Strategic Alternatives
Via ACCESS Newswire
Bausch Health to Announce Fourth Quarter and Full Year 2024 Results on February 19, 2025
Via ACCESS Newswire
Bausch Health Statement on Selection of XIFAXAN(R) (rifaximin) for Inflation Reduction Act's Medicare Negotiation Program
Via ACCESS Newswire
Bausch Health Announces Third Quarter 2024 Results
Via ACCESSWIRE
Bausch Health Announces 2024 Gastrointestinal Health Scholars Program Winners
Via ACCESSWIRE
Bausch Health Responds to Rumors of a Potential Sale of Bausch + Lomb
Via ACCESSWIRE
Bausch Health and Salix in Collaboration with Health Organizations Recognize the Second Annual Opioid-Induced Constipation (OIC) Awareness Day
Via ACCESSWIRE
Bausch Health Appoints New Chief Medical Officer and Head of R&D
Via ACCESSWIRE
Bausch Health and Salix to Present at the American Association for the Study of Liver Disease (AASLD) the RED-C Phase 3 Study Design for a New Investigational Product Designed to Address Serious Complications of Cirrhosis
Via ACCESSWIRE
PrCABTREOTM (clindamycin phosphate, adapalene and benzoyl peroxide gel) Treatment for Acne Vulgaris Receives Positive Reimbursement Recommendations from Canada's Drug Agency and Quebec's INESSS
Via ACCESSWIRE
Bausch Health Announces Second Quarter 2024 Results
Via ACCESSWIRE
Bausch Health Responds to Market Rumors
Via ACCESSWIRE
ACG Presidential Plenary to Highlight Analysis of Xifaxan(R) (rifaximin) Risk Reduction of Overt Hepatic Encephalopathy (OHE) Recurrence
Via ACCESSWIRE
Bausch Health to Announce Third Quarter 2024 Results on October 30, 2024
Via ACCESSWIRE
Bausch Health and Salix Survey Highlights Urgent Need for Improved Understanding of Liver Disease Across Healthcare Provider Disciplines as Prevalence of Cirrhosis Rises
Via ACCESSWIRE
Bausch Health Welcomes Two New Members to the Executive Leadership Team
Via ACCESSWIRE
Bausch Health to Announce Second Quarter 2024 Results on August 1, 2024
Via ACCESSWIRE
Bausch Health Brings Patent Infringement Lawsuit Against Norwich Pharmaceuticals
Via ACCESSWIRE
Bausch Health Announces 2024 Annual Meeting of Shareholder Results
Via ACCESSWIRE
Bausch Health Reports Promising R&D Trial Updates on Amiselimod and Scientific Data Presented at International Healthcare Conferences
Via ACCESSWIRE
Bausch Health, Canada Inc. Announces Additional Public Drug Plan Listings for PrUCERIS(R) (Budesonide) Aerosol Foam To Treat Mild to Moderate Distal Ulcerative Colitis in Adults
Via ACCESSWIRE
Salix to Present Late-Breaking Data from Phase 2 Trial of Amiselimod in Active Ulcerative Colitis at Digestive Disease Week 2024
Via ACCESSWIRE
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.